Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL859221 | 0.79 | DYRK1A (0.51) | ALOX12CYP1A2TDP1KDRMAPK1 | |
| SCHEMBL22633838 | 0.78 | NR1I3 (0.48) | ALOX12CYP1A2TDP1KDRMAPK1 | |
| SCHEMBL22633809 | 0.77 | NPC1 (0.57) | KDRALDH1A1MAPT | |
| SCHEMBL1398900 | 0.75 | CYP1A2 (0.40) | ALOX12CYP1A2TDP1KDRMAPK1 | |
| SCHEMBL14181838 | 0.75 | CYP1A2 (0.47) | ALOX12CYP1A2TDP1KDRMAPK1 | |
| SCHEMBL15181721 | 0.74 | CYP1A2 (0.37) | ALOX12CYP1A2TDP1KDRMAPK1 | |
| SCHEMBL6417811 | 0.74 | PKM (0.39) | ALOX12CYP1A2TDP1KDRMAPK1 | |
| SCHEMBL10994685 | 0.73 | CYP1A2 (0.70) | ALOX12CYP1A2TDP1MAPK1PKM | |
| SCHEMBL21894538 | 0.72 | ALOX12 (0.59) | ALOX12CYP1A2TDP1KDRMAPK1 | |
| SCHEMBL21760698 | 0.72 | ALOX12 (0.59) | ALOX12CYP1A2TDP1KDRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| US-8314098-B2 | Pyrazolo-pyrimidine compounds | AJINOMOTO CO., INC. (JP) | 2012-11-20 | — | — | US | disclosed |
| US-20110294781-A1 | PYRAZOLO-PYRIMIDINE COMPOUNDS | AJINOMOTO CO., INC. (JP) | 2011-12-01 | — | — | US | disclosed |
| EP-1305026-B1 | BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS | NOVUSPHARMA SPA (IT) | 2009-05-13 | — | — | EP | disclosed |
| EP-1212299-B1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LTD (GB) | 2009-04-08 | — | — | EP | disclosed |
| US-20080113993-A1 | BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS | VIA ARIOSTO, 23 (IT) | 2008-05-15 | — | — | US | disclosed |
| US-20080113993-A1 | BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS | VIA ARIOSTO, 23 (IT) | 2008-05-15 | — | — | US | disclosed |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1556349-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | Astrazeneca AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004033427-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294781-A1 | PYRAZOLO-PYRIMIDINE COMPOUNDS | IL23R, IL2, IL17A | ALOX12 74/4885CYP1A2 566/4885TDP1 4256/4885 |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | ALOX12 186/4885CYP1A2 540/4885TDP1 1034/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | ALOX12 396/4885CYP1A2 611/4885TDP1 1095/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | ALOX12 186/4885CYP1A2 540/4885TDP1 1034/4885 |
| US-20080113993-A1 | BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS | HIF1A, HIF1AN, PDGFA | ALOX12 3122/4885CYP1A2 2930/4885TDP1 2572/4885 |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | HSD11B1, HSD3B1, P4HA1 | ALOX12 385/4885CYP1A2 53/4885TDP1 3188/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | ALOX12 186/4885CYP1A2 540/4885TDP1 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.